4//SEC Filing
Pontifax Management 4 G.P. (2015) Ltd. 4
Accession 0001415889-20-001306
CIK 0001035354other
Filed
May 21, 8:00 PM ET
Accepted
May 22, 4:10 PM ET
Size
33.2 KB
Accession
0001415889-20-001306
Insider Transaction Report
Form 4
Pontifax Management Fund III L.P.
10% Owner
Transactions
- Award
Stock Option (Right to Buy)
2020-05-20+20,000→ 20,000 total(indirect: See Footnote)Exercise: $3.39Exp: 2030-05-20→ Common Stock (20,000 underlying) - Award
Stock Option (Right to Buy)
2020-05-20+20,000→ 20,000 total(indirect: See Footnote)Exercise: $3.39Exp: 2030-05-20→ Common Stock (20,000 underlying)
Pontifax (Cayman) III, L.P.
10% Owner
Transactions
- Award
Stock Option (Right to Buy)
2020-05-20+20,000→ 20,000 total(indirect: See Footnote)Exercise: $3.39Exp: 2030-05-20→ Common Stock (20,000 underlying) - Award
Stock Option (Right to Buy)
2020-05-20+20,000→ 20,000 total(indirect: See Footnote)Exercise: $3.39Exp: 2030-05-20→ Common Stock (20,000 underlying)
Pontifax (Israel) III, L.P.
10% Owner
Transactions
- Award
Stock Option (Right to Buy)
2020-05-20+20,000→ 20,000 total(indirect: See Footnote)Exercise: $3.39Exp: 2030-05-20→ Common Stock (20,000 underlying) - Award
Stock Option (Right to Buy)
2020-05-20+20,000→ 20,000 total(indirect: See Footnote)Exercise: $3.39Exp: 2030-05-20→ Common Stock (20,000 underlying)
Transactions
- Award
Stock Option (Right to Buy)
2020-05-20+20,000→ 20,000 total(indirect: See Footnote)Exercise: $3.39Exp: 2030-05-20→ Common Stock (20,000 underlying) - Award
Stock Option (Right to Buy)
2020-05-20+20,000→ 20,000 total(indirect: See Footnote)Exercise: $3.39Exp: 2030-05-20→ Common Stock (20,000 underlying)
Transactions
- Award
Stock Option (Right to Buy)
2020-05-20+20,000→ 20,000 total(indirect: See Footnote)Exercise: $3.39Exp: 2030-05-20→ Common Stock (20,000 underlying) - Award
Stock Option (Right to Buy)
2020-05-20+20,000→ 20,000 total(indirect: See Footnote)Exercise: $3.39Exp: 2030-05-20→ Common Stock (20,000 underlying)
Pontifax (Cayman) IV L.P.
10% Owner
Transactions
- Award
Stock Option (Right to Buy)
2020-05-20+20,000→ 20,000 total(indirect: See Footnote)Exercise: $3.39Exp: 2030-05-20→ Common Stock (20,000 underlying) - Award
Stock Option (Right to Buy)
2020-05-20+20,000→ 20,000 total(indirect: See Footnote)Exercise: $3.39Exp: 2030-05-20→ Common Stock (20,000 underlying)
Pontifax (China) IV L.P.
10% Owner
Transactions
- Award
Stock Option (Right to Buy)
2020-05-20+20,000→ 20,000 total(indirect: See Footnote)Exercise: $3.39Exp: 2030-05-20→ Common Stock (20,000 underlying) - Award
Stock Option (Right to Buy)
2020-05-20+20,000→ 20,000 total(indirect: See Footnote)Exercise: $3.39Exp: 2030-05-20→ Common Stock (20,000 underlying)
Pontifax (Israel) IV, L.P.
10% Owner
Transactions
- Award
Stock Option (Right to Buy)
2020-05-20+20,000→ 20,000 total(indirect: See Footnote)Exercise: $3.39Exp: 2030-05-20→ Common Stock (20,000 underlying) - Award
Stock Option (Right to Buy)
2020-05-20+20,000→ 20,000 total(indirect: See Footnote)Exercise: $3.39Exp: 2030-05-20→ Common Stock (20,000 underlying)
Pontifax IV GP L.P.
10% Owner
Transactions
- Award
Stock Option (Right to Buy)
2020-05-20+20,000→ 20,000 total(indirect: See Footnote)Exercise: $3.39Exp: 2030-05-20→ Common Stock (20,000 underlying) - Award
Stock Option (Right to Buy)
2020-05-20+20,000→ 20,000 total(indirect: See Footnote)Exercise: $3.39Exp: 2030-05-20→ Common Stock (20,000 underlying)
Footnotes (3)
- [F1]The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 20, 2021 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.
- [F2]The reported securities are owned directly by Tomer Kariv, a director of Pontifax Management 4 G.P. (2015) Ltd. and Pontifax Management III G.P. (2011) Ltd. (collectively, "Pontifax"). Pontifax Management 4.G.P. (2015) Ltd., is the general partner of Pontifax Management 4 G.P. L.P., which is the general partner of each of Pontifax (Cayman) IV L.P., Pontifax (China) IV L.P. and Pontifax (Israel) IV L.P. Pontifax Management III G.P. (2011) Ltd. is the general partner of Pontifax Management Fund III L.P., which is the general partner of each of Pontifax (Cayman) III L.P. and Pontifax (Israel) III L.P. Mr. Kariv will assign the economic interests of the reported securities to Pontifax; and Pontifax may be deemed the indirect beneficial owner of the security. Pontifax disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein.
- [F3]The reported securities are owned by Ran Nussbaum, a director of Pontifax. Mr. Nussbaum will assign the economic interests of the reported securities to Pontifax and Pontifax may be deemed the indirect beneficial owner of the security. Pontifax disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein.
Documents
Issuer
Eloxx Pharmaceuticals, Inc.
CIK 0001035354
Entity typeother
IncorporatedIsrael
Related Parties
1- filerCIK 0001726334
Filing Metadata
- Form type
- 4
- Filed
- May 21, 8:00 PM ET
- Accepted
- May 22, 4:10 PM ET
- Size
- 33.2 KB